Hepatitis C, Chronic: Clinical Trials

227 trials for Hepatitis C, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

194 completed, 17 unknown, 13 terminated, 3 withdrawn. 227 Phase 2, 26 Phase 1, 19 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2227Completed 194, Unknown 17, Terminated 13, Withdrawn 3
Phase 126Completed 20, Terminated 4, Unknown 1, Withdrawn 1
Phase 319Completed 13, Unknown 4, Terminated 1, Withdrawn 1

Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic

Trials (filtered) newest first · largest first

All 227 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.2752023-05-302025-10-21
Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects
AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic
Phase 1 / Phase 2WithdrawnAtea Pharmaceuticals, Inc.2021-10-012022-06-08
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C
Phase 1 / Phase 2CompletedSunshine Lake Pharma Co., Ltd.242020-07-062020-09-10
Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA).
Prolonged-Release Pirfenidone - Liver Cirrhosis, Hepatitis C, Chronic
Phase 2UnknownUniversity of Guadalajara602019-08-012023-07-06
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.102019-06-202020-05-04
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic
Phase 2 / Phase 3UnknownNanjing Sanhome Pharmaceutical, Co., Ltd.4402019-03-292019-08-28
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy
Phase 1 / Phase 2CompletedAin Shams University242019-03-012023-08-22
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
CDI-31244, SOF/VEL - Chronic Hepatitis C
Phase 2CompletedCocrystal Pharma, Inc.122018-06-262021-04-28
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
20mg ezetimibe, Placebo, 40mg ezetimibe - Chronic Hepatitis C
Phase 2TerminatedVA Office of Research and Development22018-04-162022-06-06
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet - Hepatitis C, Chronic
Phase 2CompletedMansoura University Children Hospital502018-03-012021-10-25
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health1502018-02-022021-05-18
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome
Phase 2 / Phase 3CompletedAin Shams University1002017-12-012018-09-20
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
SOF/VEL - Chronic Hepatitis C
Phase 2CompletedGilead Sciences592017-03-222020-03-06
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV)
Phase 2 / Phase 3CompletedAbbVie1292017-03-202023-05-09
Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C
KW-136, Sofosbuvir - Hepatitis C, Chronic
Phase 2CompletedKawin Technology Share-holding Co., Ltd.1102017-02-152018-01-31
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic
Phase 2CompletedJanssen Pharmaceutical K.K.332016-12-212019-09-11
Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients
Ombitasvir, Paritaprevir and Ritonavir - Chronic Hepatitis c
Phase 2UnknownAin Shams University402016-11-092018-01-18
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic
Phase 2CompletedJanssen Research & Development, LLC3652016-11-092019-11-20
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
LDV/SOF - Hepatitis C Virus Infection
Phase 2CompletedGilead Sciences192016-08-282020-03-02
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Uprifosbuvir 450 mg, Ruzasvir 60 mg - Hepatitis C, Chronic
Phase 2TerminatedMerck Sharp & Dohme LLC1602016-05-032019-06-26

Showing 20 of 227. Sign in to see all of them.

Narrower conditions

Hepatitis C (85)  ·  Hepatitis (12)  ·  Liver Diseases (9)  ·  Fibrosis (6)  ·  Virus Diseases (6)  ·  HIV Infections (5)  ·  Liver Cirrhosis (4)  ·  Bronchiolitis Obliterans Syndrome (3)  ·  Hepatitis, Chronic (3)  ·  Infections (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Directly Observed Therapy (2)  ·  Hepatitis, Viral, Human (2)  ·  Insulin Resistance (2)

Broader conditions

Blood-Borne Infections (227)  ·  Chronic Disease (227)  ·  Communicable Diseases (227)  ·  Disease Attributes (227)  ·  Pathologic Processes (227)  ·  Pathological Conditions, Signs and Symptoms (227)  ·  Digestive System Diseases (226)  ·  Flaviviridae Infections (226)  ·  RNA Virus Infections (226)  ·  Hepatitis, Viral, Human (225)  ·  Hepatitis, Chronic (224)  ·  Infections (224)  ·  Virus Diseases (221)  ·  Liver Diseases (218)  ·  Hepatitis (215)

Interventions

Ribavirin (115)  ·  peginterferon alfa-2a (59)  ·  Sofosbuvir (20)  ·  peginterferon alfa-2b (18)  ·  Ritonavir (16)  ·  daclatasvir (13)  ·  Simeprevir (12)  ·  ombitasvir (11)  ·  telaprevir (11)  ·  paritaprevir (10)  ·  danoprevir (9)  ·  ledipasvir (8)  ·  nitazoxanide (8)  ·  GS-9451 (7)  ·  N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (6)

Sponsors

Merck Sharp & Dohme LLC (23)  ·  Gilead Sciences (16)  ·  Hoffmann-La Roche (15)  ·  AbbVie (12)  ·  Bristol-Myers Squibb (8)  ·  Boehringer Ingelheim (7)  ·  Vertex Pharmaceuticals Incorporated (7)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6)  ·  Romark Laboratories L.C. (6)  ·  AbbVie (prior sponsor, Abbott) (4)  ·  BioWest Therapeutics Inc (4)  ·  French National Agency for Research on AIDS and Viral Hepatitis (4)  ·  GlaxoSmithKline (4)  ·  ANRS, Emerging Infectious Diseases (3)  ·  Ain Shams University (3)

Countries

United States (90)  ·  France (35)  ·  Germany (34)  ·  Puerto Rico (31)  ·  Canada (27)  ·  Spain (22)  ·  United Kingdom (20)  ·  Australia (19)  ·  New Zealand (16)  ·  Belgium (15)  ·  Poland (14)  ·  Austria (13)  ·  Egypt (13)  ·  Taiwan (11)  ·  Italy (9)

Top investigators

Asem Elfert, MD (4)  ·  Jim Pankovich (4)  ·  Armen Asatryan, MD (3)  ·  Marc G Ghany, M.D. (3)  ·  Yehia El-Gohary, MD (3)

Results publications

PMID 30012435, PMID 30923816, PMID 30977945, PMID 24154738, PMID 24209977, PMID 26596948, PMID 28412293, PMID 31568620, PMID 15282352, PMID 15563253, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 18435468, PMID 18666223, PMID 18771667, PMID 19403902, PMID 19403903, PMID 19447518, PMID 20492507, PMID 20622678, PMID 20692693, PMID 20709593, PMID 20721883, PMID 20854821, PMID 21034680, PMID 21255610, PMID 21837752, PMID 22024518, PMID 22155914, PMID 22166557, PMID 22256805, PMID 22387529, PMID 22797645, PMID 22863266, PMID 22885330, PMID 23070151, PMID 23190183, PMID 23383655, PMID 23410147, PMID 23439259, PMID 23439365, PMID 23499440, PMID 23504694, PMID 23558093, PMID 23811112, PMID 23890273, PMID 23944300

NIH funding

2014 (6), 2009 (5), 2015 (4), 2004 (2), 2008 (2), 2016 (2), 2019 (2), R01DA026727 (2), 2005 (1)